🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
375

Quick answer

First People's Hospital has 375 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  2. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  3. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

  4. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  5. TmBU conditioning Regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  7. Toripalimab

    The First People's Hospital of Lianyungang

    Adenocarcinoma of the Stomach

    phase 2 small molecule active

    1 trial

  8. Toripalimab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  10. Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  11. Toripalimab

    The First People's Hospital of Lianyungang

    Pancreatic Carcinoma

    phase 2 small molecule active

    1 trial

  12. Toripalimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule terminated

    1 trial

  13. Toripalimab

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  14. Toripalimab+Nedaplatin+Albumin Paclitaxel

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Total Neoadjuvant Treatment

    The First People's Hospital of Lianyungang

    Biliary Tract Neoplasms

    phase 2 small molecule active

    1 trial

  16. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. Trilaciclib

    The First People's Hospital of Lianyungang

    Osteosarcoma

    phase 2 small molecule active

    1 trial

  18. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  19. US-guided RFA

    The First People's Hospital of Lianyungang

    Liver Cancer

    phase 2 other active

    1 trial

  20. US-guided laser ablation for refractory neoplasms

    The First People's Hospital of Lianyungang

    Refractory Neoplasms

    phase 2 other active

    1 trial

  21. VACl

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  22. VATS

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other active

    1 trial

  23. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Adult T-cell Leukemia/Lymphoma

    phase 2 small molecule active

    1 trial

  24. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Myelodysplastic Neoplasms

    phase 2 small molecule active

    1 trial

  25. VEN+AZA+Modified BUCY

    The First People's Hospital of Lianyungang

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 2 small molecule active

    2 trials

  26. Venetoclax

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  27. Venetoclax

    The First People's Hospital of Lianyungang

    Early T Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  28. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Leukemia of Ambiguous Lineage

    phase 2 small molecule active

    1 trial

  29. Venetoclax, Azacitidine

    The First People's Hospital of Lianyungang

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  30. Venetoclax；Azacitidine；Homoharringtonine

    The First People's Hospital of Lianyungang

    Secondary Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  31. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial

  32. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  33. YPEG-rhEPO

    The First People's Hospital of Lianyungang

    Renal Anemia of Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  34. Yougui granules

    The First People's Hospital of Lianyungang

    Renal Insufficiency, Chronic

    phase 2 small molecule terminated

    1 trial

  35. Zanubrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  36. Zanubrutinib

    The First People's Hospital of Lianyungang

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  37. Zanubrutinib+Rituximab+Lenalidomide

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  38. Zoladex

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  39. Zopiclone

    The First People's Hospital of Lianyungang

    Insomnia Chronic

    phase 2 small molecule completed

    1 trial

  40. anlotinib +TQB2450 + Oxaliplatin+S-1

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

    phase 2 small molecule active

    1 trial

  41. anlotinib combined with penpulimab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. anlotinib+TQB2450+nab-paclitaxel+cisplatin

    The First People's Hospital of Lianyungang

    Advanced Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  43. anti-CD7 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  44. anti-FLT3 CAR-T

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  45. anti-MUC1 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  46. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  47. cadonilizumab combined with neoadjuvant radiochemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  48. cardonilizumab combined with renvastinib

    The First People's Hospital of Lianyungang

    Resectable Clear Cell Carcinoma of the Kidney

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

375 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.